Table 1.

Clinicopathologic and molecular features

All patients in phase I and Ib, n = 152n (%)a
Age, years63 (27–90)
Sex
 Female79 (52)
 Male73 (48)
Tumor type
 NSCLC81 (54)
  Nonsquamous69 (46)
  Squamous12 (8)
 Gastrointestinal cancer39 (25)
  Colorectal28 (18)
  Other (hepatocellular, pancreas)11 (7)
 Thyroid cancer17 (11)
 Other cancers (head and neck, ovarian, primary brain tumor)15 (10)
Number of prior systemic therapies
 016 (11)
 1–257 (36)
 3 or more79 (53)
Patients in phase Ib, n = 97n (%)
Cohorts
RET fusion–positive lung cancer, TKI-naïve31 (33)
  KIF5B–RET20 (65)
  CCDC6–RET6 (20)
  EML4–RET2 (6)
  PARD3–RET1 (3)
  Unknown (FISH-positive)2 (6)
RET fusion–positive lung cancer, prior TKI9 (9)
RET-altered solid tumor (non-lung), TKI-naïve1 (1)
BRAFV600E-mutant lung cancer, TKI-naïve7 (7)
BRAFV600E-mutant colorectal cancer, TKI-naïve9 (9)
BRAFV600E-mutant cancer (non-lung, non-melanoma)8 (8)
 Squamous cell lung cancer9 (9)
 Other cancers23 (24)
  • NOTE: The demographics, tumor types, and number of prior therapies of all patients enrolled onto the phase I and phase Ib portions of this study are summarized. In addition, for RET tyrosine kinase inhibitor (TKI)–naïve patients with RET fusion–positive lung cancers enrolled onto the phase Ib portion, the RET fusion type is shown.

  • aExcept for age for which median and range are shown.